Fixed-dose combination (antiretroviral)
From Wikipedia, the free encyclopedia
Fixed-dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill, which helps reduce pill burden. They may combine different classes of antiretrovirals or contain only a single class. Licensed fixed-dose combinations are shown in the table below.
| Brand Name | Drug Names (INN) | Date of FDA Approval | Company |
|---|---|---|---|
| Combivir | zidovudine + lamivudine | September 26, 1997 | GlaxoSmithKline |
| Trizivir | abacavir + zidovudine + lamivudine | November 15, 2000 | GlaxoSmithKline |
| Kaletra | lopinavir + ritonavir | September 15, 2000[1] | Abbott Laboratories |
| Epzicom (in USA) Kivexa (in Europe) |
abacavir + lamivudine | August 2, 2004 | GlaxoSmithKline |
| Truvada | emtricitabine + tenofovir | August 8, 2006[2] | Gilead Sciences |
| Atripla | efavirenz + emtricitabine + tenofovir | July 12, 2006[3] | Gilead Sciences Bristol-Myers Squibb |
| Complera | rilpivirine + emtricitabine + tenofovir | August 10, 2011[4] | Gilead Sciences Johnson & Johnson |
| Stribild | elvitegravir + cobicistat + emtricitabine + tenofovir | August 27, 2012 | Gilead Sciences |
See also [edit]
References [edit]
- ^ "FDA approval of new formulation of Kaletra". FDA. October 28, 2005. "The original formulation was approved on September 15, 2000"
- ^ "Traditional approval of Viread and Truvada". FDA. March 8, 2006. "VIREAD and TRUVADA had received accelerated approval on Oct. 26, 2001 and August 2, 2004, respectively"
- ^ "FDA approval of Atripla, 3-drug fixed dose combination antiretroviral". FDA. July 12, 2006.
- ^ "Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination". FDA. August 10, 2011.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
